Background and aims: Morbid obesity is an emerging problem in the inflammatory bowel disease [IBD] population. Bariatric and IBD surgeries share technical difficulties and elevated morbidity. However, nothing is known about the possibility of performing bariatric surgery in patients with a definite diagnosis of IBD. The aim of this study was to evaluate safety and efficacy of restrictive bariatric surgical procedures in IBD patients. Methods: Six patients with morbid obesity and IBD were operated on with restrictive bariatric surgery and concomitant or deferred IBD surgery. We compared BMI, excess weight loss, and perioperative complications of restrictive bariatric surgery in IBD with a control group of 95 bariatric patients. We also evaluated clinical, biochemical, pharmacological, and endoscopic characteristics before and after surgery in IBD patients. Results: Perioperative results, in terms of BMI, excess weight loss, and complications after restrictive bariatric surgery, were comparable between obese IBD and control patients. IBD patients experienced a significant postoperative reduction in BMI, CRP levels, WCC, and systolic blood pressure and a significant increment in hemoglobin levels. None of the patients reported signs of malabsorption. All the patients except one were able to discontinue steroids, were in endoscopic remission at 1 year, and were in clinical remission at the latest follow-up visit. Two patients halved azathioprine dosage. One patient had a postoperative clinical recurrence treated with adalimumab. Conclusions: Bariatric surgery seems to be safe and effective in IBD patients. Concomitant ileocolic resection does not increase perioperative complications. Relationship between IBD and obesity remains unclear, but weight loss could be useful in the pharmacological control of IBD.
Introduction
Morbid obesity and inflammatory bowel diseases [IBD] are growing social and medical problems worldwide. Obesity is associated to immune system dysregulation, resulting in low-grade chronic inflammation mediated by a number of cytokines, such as interleukin-6 and tumur necrosis factor-alpha [TNFα] , which play a central role also in IBD. 1 Pharmacological treatment of obese patients is challenging, due to the large volume of distribution. 2, 3 Recent reports suggest a prevalence of morbid obesity in IBD patients of 15-20%, especially in those with Crohn's disease [CD] . 4 A body mass index [BMI] over 35, with related comorbidities, is a definite indication for bariatric surgery in order to avoid long-term complications. The two main surgical approaches are restrictive [reduction of gastric volume] or malabsorptive [bypass] , depending on BMI and comorbidities.
Bariatric and IBD surgeries share technical difficulties and elevated morbidity. However, nothing is known about the possibility of performing a bariatric operation in patients with a definite diagnosis of IBD, or combining bariatric and IBD surgery.
The aim of the present study was to evaluate safety and efficacy of bariatric surgery in obese IBD patients.
Materials and Methods
Between January 2007 and December 2012, 161 morbid obese patients and 418 IBD patients [310 with Crohn's disease, 108 with ulcerative colitis [UC] ] underwent surgery at the Department of Surgery, 'Luigi Sacco' University Hospital in Milan, Italy. Six patients [5 CD and 1 UC] presented with both morbid obesity and IBD, and received a bariatric operation with concomitant or deferred IBD surgical treatment. In all patients, clinical, hematologic, radiologic, endoscopic and surgical data were prospectively collected in the 'Luigi Sacco' IBD computerized database, approved by the Ethical Committee. In particular, IBD patients were screened for gastric and jejuno-ileal CD locations through a recent gastroduodenoscopy and magnetic resonance imaging [MRI] of the small bowel. The patients were classified for IBD using the Montreal Classification. 5 All the patients had a long history of obesity with many attempts at weight reduction with diet and improvement of physical activity. The decision to operate was taken after the evaluation of the patient during a regular IBD multidisciplinary meeting [MDM] , on the basis of clinical, radiologic and endoscopic findings, in the presence of the senior bariatric surgeon [DF] . Postoperative scheduled follow-up was performed at 3, 6, and 12 months for the first year and every 6 months for the next 4 years. Endoscopic remission of CD was evaluated at 12 months. The latest follow-up up dating was June 2014. Postoperative complications were reported as intra-abdominal septic complications [IASC] related to the surgical procedure. Clinical recurrence was defined as the presence of CD-related symptoms associated with radiologic, endoscopic, and laboratory findings requiring treatment with high doses of steroids or an induction regimen with anti-TNFα agents. Ileocaecal resections were performed as minimal resections with macroscopic, but not microscopic, disease-free margins as previously reported. [6] [7] [8] [9] [10] Bariatric procedures were performed using restrictive, and not malabsorptive, techniques [ Figure 1 ].
A specific informed consent was obtained from all the patients. In order to assess safety and efficacy of bariatric surgery in IBD patients, we used as a control group all the morbid obese patients submitted to restrictive surgery in the same period. We compared weight, BMI, excess weight loss, and perioperative complications [IASC] Preoperative patients characteristics are reported in Table 1 . The number of preoperative clinical relapses is reported with all the pharmacological shifts adopted. Surgical procedures, pre-and postoperative clinical, biochemical, and endoscopic assessments are listed in Table 2 . In particular, the indication for surgery in cases 5 and 6 was fibrostenotic disease of the terminal ileum. Figure 1 ]. She presented with recurrent vomiting and dysphagia. The stomach had a clepsydra shape and it was technically impossible to perform a sleeve gastrectomy. She underwent to a gastrectomy with short limbs, Roux-en-Y, gastric bypass in order to minimize malabsorption. Case 2 experienced a complete healing of the rectum and perianal fistulas; he had his colostomy closed in 2009; and he was asymptomatic with deep disease remission at latest follow-up visit. Case 3, 2 years after bariatric surgery, underwent to a total abdominal colectomy for a colorectal cancer in the sigmoid colon [pT3N0M0G2] discovered during regular endoscopic screening. She received adjuvant chemotherapy, and in 2012 she underwent proctectomy and ileo-pouch-anal anastomosis with a 'J' pouch.
Comparisons between IBD and non-IBD obese patients in terms of BMI, excess weight loss, and perioperative complications are reported in Table 3 . There were eight perioperative complications in the non IBD group [three gastric bleeding, four fistula, one gastric stenosis] that required three reoperations. There was one gastric suture bleeding in the IBD group and no reoperations. No statistical significance was found between the two groups.
Discussion
Obesity is a public health problem that has reached epidemic proportions worldwide, involving both rich and poor countries, with an estimated 500 millions obese adults and 1.5 billion overweight or obese people. 1, [16] [17] [18] In recent years, obesity has been associated with chronic systemic inflammation due to the innate immune system activation in adipose tissue that promotes an increase in the production and release of pro-inflammatory cytokines.
1,2,3,18 Recent reports seem to show an emerging trend toward overweight in mild or quiescent CD, reflecting adequate control of inflammation, older age, and sedentary lifestyle. The prevalence of obese patients in IBD population, especially in CD, has been reported at 15-20%. 16, 19 However, the relationship between obesity and IBD has been poorly investigated.
Blain et al. 2 compared obese with non-obese CD patients and found that obesity in Crohn's disease was associated with perianal complications and year-by-year disease activity, but not with the long-term disease course. The hypothesis was that increased friction and sweating between the skin folds of the perineum encouraged maceration and secondary bacterial infections, favouring abscess formation. They concluded that obesity is not a risk factor for Crohn's disease as for other chronic inflammatory disease [eg rheumatoid arthritis].
Hass et al. 3 evaluated CD overweight patients in terms of age at diagnosis, time to first surgery, total number of surgical procedures, and therapy escalation. They showed that CD patients with a BMI ≥25 kg/m 2 were older at diagnosis, with a shorter time to first surgery. Their hypothesis was that overweight patients could have a more aggressive disease or they could be less responsive to immunomodulators due to the pharmacological volume of distribution.
The American College of Surgeons National Surgical Quality Improvement Program Database [2005] [2006] [2007] [2008] 18 has shown longer operating times and higher overall postoperative morbidity in obese patients after major surgery for complicated Crohn's disease. Similarly, longer operating times and higher morbidity has been reported in UC patients submitted to restorative proctocolectomy, including a significantly increased risk of pelvic sepsis. 14 In their review, Boutros and Maron 16 confirmed that both obesity and IBD heighten the complexity of surgery and postoperative care, and obesity alone enhances the technical difficulties and the risk of complications of IBD surgery.
There are some reports in the literature suggesting that bariatric surgery is a potential risk factor for the development of CD. [21] [22] [23] Ahn et al. 23 described three young adults, without family history of IBD or previous gastrointestinal disease, who developed CD 11 to 60 months after Roux-en-Y gastric bypass procedure. Some authors postulated that anatomic changes after malabsorptive bariatric surgery might promote a bacterial overgrowth that should trigger intestinal chronic inflammation. However, little is known about the interaction of bariatric and IBD surgery in patients with a definite diagnosis of IBD, or the impact of bariatric surgery on IBD course. 24 Lascano et al. 25 described a 39-year-old male affected by UC, hypertension, and morbid obesity, who after gastric bypass experienced clinical remission of UC and reduction in medications.
There are no reports to date on outcomes of ileoanal pouch procedure in patients with previous bariatric surgery. We described a UC patient who after a sleeve gastrectomy underwent a restorative proctocolectomy without complications and good functional results.
In our series we adopted a restrictive bariatric procedure, since nothing is known about the possible impact of a malabsorptive bypass in an IBD patient. Using this approach, we reached effective results in BMI reduction without significant perioperative complications or intestinal malabsorption. Furthermore, in those patients treated with concomitant IBD surgery we did not experience the possible mutual increase of complications. We registered a normalization of inflammatory markers, hemoglobin levels, and systolic blood pressure in patients with concomitant or deferred IBD surgery. The patient who experienced a postoperative clinical recurrence, treated with an anti-TNFα compound, might have a particularly aggressive CD. In fact, the patient had undergone two small bowel resections in the previous 5 years.
Since this is a small case series, it is impossible to know whether the positive trend in inflammation, in those patients who underwent bariatric and IBD surgery, might have a benefit not only in weight loss but also in the removal of the active inflammatory bowel disease. However, most of the patients were non-responders to medical treatment with several therapeutic shifts prior to bariatric surgery. An intriguing hypothesis should be that on the one hand we have reduced systemic inflammation through the component due to obesity, on the other hand the fall of BMI has reduced the pharmacological volume of distribution to the normal therapeutic range.
In conclusion, further studies are needed to better understand the relationship between IBD and morbid obesity in terms of therapy and complications. Restrictive bariatric surgery in IBD patients should be considered in selected, highly motivated patients, nonresponder to pharmacological treatment.
